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Background
The family of 6-phospofructo-2-kinase/fructose-2,6-bis-
phosphatases (PFKFB1-4) control glycolytic flux via their
product, fructose-2,6-bisphosphate (F26BP), which
activates the key control step, 6-phosphofructo-1-kinase
(PFK-1). We recently demonstrated that exposure of
estrogen receptor (ER)+ MCF-7 human breast cancer cells
to estradiol (E2) causes a rapid increase in 14C-glucose
uptake and glycolysis that is coincident with an induction
of PFKFB3 mRNA (via ER binding to its promoter),
protein expression and the intracellular concentration of
its product, F26BP. Selective inhibition of PFKFB3 expres-
sion and activity using siRNA or a PFKFB3 inhibitor,
PFK158, markedly reduced the E2-mediated increase in
F26BP, 14C-glucose uptake and glycolysis. Importantly,
co-treatment of MCF-7 cells with PFK158 and an ER
antagonist synergistically induced apoptotic cell death
in vitro. In the current study, we sought to determine
if co-administration of PFK158, with ICI 182,780
(fulvestrant), would have an additive anti-tumor effect
on ER+ human breast cancer xenografts in vivo.
Materials and methods
Methods included apoptosis assays, measurements of
14C-glucose uptake and glycolysis, and an E2-dependent
ER+ MCF-7 xenograft model of breast tumorigenesis.
Results
Initially, we found that the inhibitory effects of PFK158 on
MCF-7 cell glycolysis but not glucose uptake lasted
24 hours after E2 exposure suggesting that flux through
PFK-1 and not the pentose shunt was the key metabolic
target of PFK158. We then confirmed that E2 upregulated
PFKFB3 in a second ER+ breast cancer cell line, T47D
cells, and found that PFK158 also synergistically increased
the apoptotic effects of ICI 182,780 in these cells. In order
to determine if there exists potential clinical utility in com-
bining PFKFB3 and ER antagonists, we next implanted
BALB/c athymic mice with 17beta-E2 pellets (dose
1.7 mg/60 days) and subcutaneously injected 107 MCF-7
cells in 100 μl of matrigel. After 7 days, mice that devel-
oped tumors >80 mg were randomized into four treatment
groups and administered DMSO, ICI 182,780, PFK158 or
the combination and tumor volumes were assessed every
three days for 45 days using microcalipers. We found that
the combination of ICI 182,780 with PFK158 yielded the
greatest anti-tumor effect in this E2-dependent model
of tumorigenesis: DMSO, 298 ± 62.86 mg; ICI 182,780,
160 ± 62.4 mg; PFK158, 142 ± 90 mg; ICI 182,780 +
PFK158, 45 ± 38 mg.
Conclusions
These results provide essential pre-clinical information
that may allow for the design of combinatorial phase I/II
trials of PFKFB3 antagonists with anti-estrogen therapies
in ER+ stage IV breast cancer patients.
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